Virtual Poster Hall

Category 1: Basic Science				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
101	B-1	Sex-specific Transcriptional Differences and Loss of Gene Imprinting in Pancreatic Neuroendocrine Tumors	Nikolay A. Ivanov, Weill Cornell Medicine, New York, NY	41
102	B-2	RNA-sequencing Identifies Unique Molecular Features of Duodenal Neuroendocrine Tumors	Catherine G. H. Tran, University of Iowa, Iowa City, IA	65
103	B-3	Cd36 Mediated Metabolic Reprogramming in Cancer Stem Cells Contributes to Drug Resistance to mTOR Inhibition in	Yichen (Hailey) Guo, The University of Alabama at Birmingham, Birmingham, AL	128
104	B-4	Loss of MEN1 Function Inhibits DNA Repair Capability of Pancreatic Neuroendocrine Tumors after Radiation	Xavier M Keutgen, University of Chicago Medicine, Chicago, IL	132
105	B-5	RABL6A-Myc Signaling Promotes Pancreatic Neuroendocrine Tumor Cell Proliferation and Survival	Umesalma Shaikamjad, University of Iowa, Iowa City, IA	147
106	B-6	Inhibition of Serotonin Biosynthesis Suppresses Tumor	Po H Ear, University of Iowa, Iowa City, IA	152
107	B-7	Succinate Accumulation Is Not Sufficient for Tumorigenesis in Mouse Chromaffin Cells But Dual Loss of SDHB and NF1 Yields SDHx-like Pheochromocytomas	Justin P. Annes, Stanford University, Stanford, CA	167
108	B-8	Development of a Real-time Luminescent Sensor for Detecting Serotonin Levels in Neuroendocrine Tumors	Dane Tow, University of Iowa Carver College of Medicine, Iowa City, IA	179
109	B-9	Natural Compound Verrucarin A Potentiates the Anticancer Effect of Etoposide in NET Cell Lines	Jason Whitt, University of Alabama at Birmingham, Birmingham, AL	181
110	B-10	Novel Fusion Gene UBTF-MAML3 Drives Tumorigenesis in Neuroendocrine Tumor Cells	Hannah E. Haas, University of Colorado, Aurora, CO	184
111	B-11	Variability of Somatostatin Receptor Type 2 Immunohistochemical Staining Patterns Among	Rachael Guenter, University of Alabama at Birmingham, Birmingham, AL	188
Category 2: Applied Basic Science				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
201	B-12	Sunitinib-loaded Chondroitin Sulfate Hydrogels as a Novel Drug-delivery Mechanism for the Treatment of Pancreatic	Xavier M. Keutgen, University of Chicago Medicine, Chicago, IL	40
202	B-13	The MAP Kinase-activated Protein Kinase 2 Promotes the Development and Progression of Pancreatic Neuroendocrine Tumors Involving Action Mediated by	Damian Jacenik, University of Utah, Salt Lake City, UT	112
203	B-14	Establishment of Two Patient-derived Neuroendocrine Carcinoma Spheroid and Xenograft Models for Drug Testing	Gabriella Beyer, University of Iowa Carver College of Medicine, Iowa City, IA	175
204	B-15	Comparison of Drug Sensitivity Profiles of Various NEN Spheroids	Catherine G. Tran, University of Iowa Carver College of Medicine, Iowa City, IA	177
205	B-16	Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma	Aman Chauhan, University of Kentucky, Lexington, KY	201
206	B-17	Pre-clinical Evaluation of Alpha-particle Radiotherapy Targeting CXCR4 in Small Cell Lung Cancer	Dijie Liu, University of Iowa, Iowa City, IA	34

Category 3: Clinical-Chemotherapy, SSA and Biologics				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
301	C-1	Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy in Patients with High-grade Extrapulmonary	Jennifer Jane Gile, Mayo Clinic, Rochester, MN	52
302	C-2	The Role of Microbiome in Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs)	Amr Mohamed, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH	60
303	C-3	Patient-reported Clinical and Productivity Outcomes From the Longitudinal Telotristat Ethyl Treatment Registry	Daneng Li, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA	98
304	C-4	An Open-Label, Phase II Investigation of Trifluridine/Tipiracil in Patients With High-Grade, Extrapulmonary	Andrew Scott Paulson, Texas Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, TX	103
305	C-5	Interim analysis results of surufatinib in US patients with neuroendocrine tumors (NETs)	Daneng Li, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA	105
306	C-6	Impact of Capecitabine and Temozolomide on the Primary Tumor in Pancreatic Neuroendocrine Tumors	Jin Guo, MD Anderson Cancer Center, Houston, TX	119
307	C-7	The Safety and Efficacy of PEN-221 Somatostatin Analog (SSA)-DM1 Conjugate in Patients (Pts) with Advanced GI Mid-gut Neuroendocrine Tumor (NET): Phase 2 Results	Daniel M. Halperin, The University of Texas MD Anderson Cancer Center, Houston, TX	120
308	C-8	Lanreotide Autogel/Depot (LAN) in Patients with Advanced Bronchopulmonary (BP) Neuroendocrine Tumors (NETs): Results From the Phase 3 SPINET Study	Diane Reidy-Lagunes, Memorial Sloan Kettering Cancer Center, New York, NY	126
309	C-9	Real World Use of Lanreotide in Management of Neuroendocrine Tumours	Zeba Siddiqui, The Ottawa Hospital, Ottawa, ON, Canada	129
310	C-10	Genomic Profiling of Responders and Non-responders to Checkpoint Inhibition in Neuroendocrine Carcinoma	Patrick W McGarrah, Mayo Clinic, Rochester, MN	131
311	C-11	Lurbinectedin in Extrapulmonary Metastatic Neuroendocrine Carcinomas	Aakash Desai, Mayoclinic, Rochester, MN	135
312	C-12	Urinary Neuroendocrine Neoplasms (NENs) Treated in the "Modern Era": A Multicenter Retrospective Review	Bryan Khuong Le, University California, San Francisco, San Francisco, CA	145
313	C-13	Health-related Quality-of-life Analysis of Surufatinib Versus Placebo for Advanced Neuroendocrine Tumors: Pooled Results From Two Phase 3 Studies (SANET-p and SANET-ep)	Chunmei Bai, Peking Union Medical College Hospital, Beijing, China	150
314	C-14	Exploring Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-	Amr Mohamed, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH	157
315	C-15	Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors	Taymeyah Al-Toubah, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL	158
316	C-16	Efficacy of Ipilimumab and Nivolumab in Patients with High-grade Neuroendocrine Neoplasms	Taymeyah Al-Toubah, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL	159
317	C-17	Treatment Response and Clinical Outcomes of Neuroendocrine Neoplasms (NENs) Treated with Immune Checkpoint Inhibitors (ICIs): a Single Institution Experience	Haley Hauser, Memorial Sloan Kettering Cancer Center, New York, NY	161
318	C-18	A Phase 2 Study of Surufatinib in Combination with Toripalimab in Patients with Advanced Neuroendocrine Carcinoma	Ming Lu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China	168
319	C-19	Phase 2 Trial of Pembrolizumab-based Therapy in Previously Treated Extrapulmonary Poorly-differentiated Neuroendocrine Carcinomas: Results of Part B	Jennifer A. Chan, Dana-Farber Cancer Institute, Boston, MA	172
320	C-20	Randomized Blinded Study Comparing Injection Site Pain From Octreotide Long-acting-release (LAR) Versus Lanreotide During the Treatment of Well-differentiated	Nitya Raj, Memorial Sloan Kettering Cancer Center, New York, NY	173

Category 4: Clinical-Nuclear Medicine, Interventional Radiology and Imaging				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
401	C-21	Validation of a Clinical Score (CS) for Patients With Well-Differentiated Neuroendocrine Tumors (WD NETs) Under Consideration for Peptide Receptor Radionuclide Therapy	Satya Das, Vanderbilt University Medical Center, Nashville, TN	31
402	C-22	Defining MRI Superiority Over CT for Neuroendocrine Liver Metastases	Marc A. Attiyeh, Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA	42
403	C-23	Long-term Outcomes Following 90YRadioembolization of Neuroendocrine Liver Metastases	Thomas Y. Wong, Vanderbilt University Medical Center, Nashville, TN	53
404	C-24	Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)	Mohmed Badawy, Mayo Clinic, Rochester, MN	54
405	C-25	Comparing Periprocedural Hemodynamic Instability in Y-90 Radioembolization and Bland Embolization for Neuroendocrine Tumor Liver Metastases	Adam Weekley, University of South Florida Morsani College of Medicine, Tampa, FL	56
406	C-26	Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single	Heying Duan, Stanford University, Stanford, CA	62
407	C-27	Subgroup Analysis by Ki-67 and Primary Tumor Origins of the Randomized, Placebo-controlled Phase 3 Study of Surufatinib in Advanced Well-differentiated Extrapancreatic Neuroendocrine Tumors (SANET-ep)	Zhiwei Zhou, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China	107
408	C-28	Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-controlled Phase 3 Study of Surufatinib in Advanced Well-differentiated Pancreatic	Xianjun Yu, Fudan University Shanghai Cancer Center, Shanghai, China	108
409	C-29	Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Advanced Pancreatic Neuroendocrine Tumours (panNETs): Data From the NETTER-R International,	Dominique Clement, King's College Hospital, London, United Kingdom	110
410	C-30	Compose: Pivotal Phase III Trial of 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic	Thorvardur R. Halfdanarson, Mayo Clinic, Rochester, MN	136
411	C-31	Safety and Effectiveness of 177Lu-Satoreotide Tetraxetan in Patients with Progressive Neuroendocrine Tumors (NETs): Interim Analysis of a Phase I/II Study	Henning Grønbæk, Aarhus University Hospital, Aarhus, Denmark	141
412	C-32	The Phase 3 NETTER-1 Study of 177Lu-DOTATATE in Patients with Midgut Neuroendocrine Tumors: Updated	Pamela L. Kunz, Yale School of Medicine, New Haven, CT	142
413	C-33	Utility of Midpoint Imaging in Patients Receiving Peptide Receptor Radionuclide Therapy (PRRT) for Advance Progressive Gastroenteropancreatic-Neuroendocrine	Aurora P. Norman, Mayo Clinic, Rochester, MN	154
414	C-34	Secondary Hematological Malignancies Following High-specific Activity Iodine-131 Metaiodobenzylguanidine Treatment of Advanced Pheochromocytoma and	Daniel A. Pryma, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA	155
415	C-35	177Lu Dotatate Peptide Receptor Radionuclide Therapy in Chronic Kidney Disease Patients: a Single Center Experience	Sandhya Manohar, Mayo Clinic, Rochester, MN	160
416	C-36	Cap-Tem-Y90 for Grade 2 Liver-dominant Net Metastases	Michael C. Soulen, Abramson Cancer Center, Philadelphia, PA	174
417	C-37	Treatment Response and Clinical Outcomes of Well-differentiated (WD) High-grade (HG) Neuroendocrine Tumors (NETs) to 177Lu-DOTATATE	Kelley Coffman, Memorial Sloan Kettering Cancer Center, New York, NY	178
418	C-38	Clinical Utility of Qualitative Post-treatment SPECT After Peptide Receptor Radionuclide Therapy	Courtney Lawhn-Heath, University of California San Francisco, San Francisco, CA	180
419	C-39	Blood-based Genomic Assessment of Clinical Efficacy and Toxicity of 177Lu-DOTATATE of Neuroendocrine Tumors	Lisa Bodei, Memorial Sloan Kettering Cancer Center, New York, NY	183
420	C-40	Hepatotoxicity From Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NETs) Patients	Denise A. Gococo-Benore, Mayo Clinic, Jacksonville, FL	190
421	C-41	Concurrent Everolimus with Hepatic Transarterial Bland Embolotherapy [Evero-Embo] in Patients with Bulky and/or Progressive Metastatic Well Differentiated Neuroendocrine	Garima Gupta, University of Kentucky Markey Cancer Center, Lexington, KY	193
422	C-42	A Case of G3-WD Gastric Carcinoid Tumor in a MEN1 Patient with Discrepant Treatment Response to PRRT in	Elcin Zan, NYU Grossman School of Health, New York, NY	198
423	C-43	MRI Has Improved Detection of Small Neuroendocrine Liver Metastasis Compared with Ga-68 DOTATATE	Gautam K. Malhotra, City of Hope, Arcadia, CA	200

Category 5: Clinical-Surgical and Applied Pathology				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
501	C-44	Multifocality Is Not Associated with Worse Survival in Sporadic Pancreatic Neuroendocrine Tumors	Hallbera Gudmundsdottir, Mayo Clinic, Rochester, MN	58
502	C-45	Management of Duodenal Neuroendocrine Tumors: Surgical Versus Endoscopic Mucosal Resection	Catherine G. H. Tran, University of Iowa, Iowa City, IA	64
503	C-46	Alternative Lengthening of Telomeres Is Associated with Aggressive Pathologic Features and Increased Recurrence Risk in Large Pancreatic Neuroendocrine Tumors	Hallbera Gudmundsdottir, Mayo Clinic, Rochester, MN	111
504	C-47	Pathologic Features of Small Pancreatic Neuroendocrine Tumors with Liver Metastasis	Chanjuan Shi, Duke University Medical Center, Durham, NC	113
505	C-48	Venous Invasion in Resected Pancreatic Neuroendocrine Tumors Is Independently Associated with Disease Free	Chanjuan Shi, Duke University Medical Center, Durham, NC	114
506	C-49	Importance of Grade in the Surgical Management of Rectal Neuroendocrine Tumors	Akie Watanabe, University of British Columbia, Vancouver, BC, Canada	115
507	C-50	Detection Method and Overall Survival in Surgically Resected Pancreatic Neuroendocrine Tumors	Lauren Slattery, University of Utah, Salt Lake City, UT	144
508	C-51	A Single-Center Experience in Observation of Small Pancreatic Neuroendocrine Tumors: To Operate or Not to	Ariana Naaseh, University of California, Irvine School of Medicine, Irvine, CA	148
509	C-52	Role of Chromogranin A in the Diagnosis and Follow up of Neuroendocrine Neoplasms: Real World Review	Mike Nguyen, Monash Health, Clayton, Australia	149
510	C-53	A Prospective Study of Carcinoid Crisis with No Perioperative Octreotide	Rodney F. Pommier, Oregon Health & Science University, Portland, OR	163
511	C-54	Differences in the Mutation of DAXX, ATRX, and MENIN in Pancreatic Neuroendocrine Tumors from Black and White	Brendon R. Herring, University of Alabama at Birmingham, Birmingham, AL	170
512	C-55	Early Onset Well Differentiated Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathologic Features, and	Alessandra Pulvirenti, Memorial Sloan Kettering Cancer Center, New York, NY	176
513	C-56	Comparison of Patients with Small Bowel Neuroendocrine Tumor Liver Metastaseswith and without Carcinoid Syndrome: A Single Institutional Analysis	Timothy P. DiPeri, Cedars Sinai Medical Center, Los Angeles, CA	182
514	C-57	HPG80 (circulating progastrin), a Novel Blood-based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated	Aman Chauhan, University of Kentucky, Lexington, KY	194

Category 6: Population Science				
Poster Number	**Category ID**	**Title**	**Poster Presenter**	**Abstract ID**
601	P-1	Predictors And Outcomes Of Minimally Invasive Surgery For Small Bowel Neuroendocrine Tumors	William G. Wong, PennState Health Milton S. Hershey Medical Center, Hershey, PA	27
602	P-2	Incidence of Psychiatric Illness in Patients With Neuroendocrine Tumors - A Comparative Population-Based	Julie Hallet, University of Toronto, Toronto, ON, Canada	74
603	P-3	Incidence and Predictors of Second Cancers in Neuroendocrine Tumors	Sarah Bateni, University of Toronto, Toronto, ON, Canada	76
604	P-4	Secondary Primary Cancers and Survival among Neuroendocrine Tumor Patients	Sarah Bateni, University of Toronto, Toronto, ON, Canada	77
605	P-5	Race is an Independent Predictor for Surgery Offer in Patients with Small Bowel Neuroendocrine Tumors But Not Pancreatic Neuroendocrine Tumors	Jorge Zarate Rodriguez, Washington University in St Louis School of Medicine, St Louis, MO	117
606	P-6	Surgical Interventions in Patients with Pancreatic Neuroendocrine Tumors: a SEER-based Survival Analysis	Jorge Zarate Rodriguez, Washington University in St Louis School of Medicine, St Louis, MO	143
607	P-7	Prevalence and Presentation of Cushing and Carcinoid Syndromes in Patients with Non-metastatic Primary Lung	Kenzie Lee, Mayo Clinic, Rochester, MN	146
608	P-8	Association Between Hospital Volume and Overall Survival of Pancreatic Neuroendocrine Tumors	Sri Harsha Tella, Mayo Clinic, Rochester, MN	153
609	P-9	The Impact of Sociodemographic Factors on Overall Survival for Patients with Adrenocortical Carcinomas in California	Claire Mulvey, UCSF, San Francisco, CA	169
610	P-10	Covid-19 in Patients with Neuroendocrine Tumors (NETs): the Mayo Clinic Experience	Sagar Rakshit, Mayo Clinic, Rochester, MN	171
611	P-11	The Epidemiology of Mixed Acinar Neuroendocrine Carcinoma of the Pancreas in the United States	Amro M. Abdelrahman, Mayo Clinic, Rochester, MN	192
612	P-12	MDT Experience in Argentina in Nets in Times of the Covid19 Pandemic	Ana Oviedo Albor, Hospital Gastroenterologia Udaondo, Buenos Aires, Argentina	151

Category 7: Other Research

Poster Number	Category ID	Title	Poster Presenter	Abstract ID
701	O-1	A Systematic Survey of Two Decades of Clinical Trials in Neuroendocrine Neoplasms (NENs)	Satya Das, Vanderbilt University Medical Center, Nashville, TN	45
702	O-2	The Feasibility and Acceptability of Health and Wellness Coaching for Neuroendocrine Tumor Patients and Their	Lisa Yen, LACNETS, Los Angeles, CA	61
703	O-3	Patient-reported Cognitive and Psychological Screening in Neuroendocrine Tumors (NETs) - a Prospective Cohort	Julie Hallet, Sunnybrook Health Sciences Centre, Toronto, ON, Canada	75
704	O-4	Neuroendocrine Tumor Treatments and Follow-up Disease Management - Comparative Perspective (U.S. and Canada	Teodora Kolarova, International Neuroendocrine Cancer Alliance, Newton, Boston, MA	101
705	O-5	Outcomes of Initial Treatment in Early Stage Neuroendocrine Carcinoma of the Uterine Cervix (NCUC)	Ashley D. Hickman, Mayo Clinic, Rochester, MN	121
706	O-6	Evaluating the Association Between Family History and Overall Survival Among Patients with Gastrointestinal and Pancreatic Neuroendocrine Tumors	Erica S. Tsang, Dana-Farber Cancer Institute, Boston, MA	134
707	O-7	Succinate Dehydrogenase Pathogenic Variants are Not Associated with Non-canonical Cancers	Heather Wachtel, University of Pennsylvania, Philadelphia, PA	187
708	O-8	Understanding Neuroendocrine Tumour Patient Preferences for Medical Management of Midgut NETs Using Discrete Choice Experiments: a DIRECT NETs Study	Matthew Anaka, University of Alberta, Edmonton, AB, Canada	195

Category 8: Trials In Progress

Poster Number	Category ID	Title	Poster Presenter	Abstract ID
801	T-1	Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects with Advanced Neuroendocrine Tumors	Bassel F. El-Rayes, Winship Cancer Institute at Emory University, Atlanta, GA	109
802	T-2	Dose Selection for Paltusotine, a Once Daily Oral Nonpeptide, Somatostatin Receptor 2 Ligand, for the Treatment of Patients with Carcinoid Syndrome (CS)	Hjalmar Lagast, Crinetics Pharmaceuticals, San Diego, CA	127
803	T-3	[177Lu]Lu-DOTA-TATE as First-line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): the NETTER-2 Study	Simron Singh, University of Toronto, Toronto, ON, Canada	138
804	T-4	A Phase II Trial to Evaluate the Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-	Sue M. O'Dorisio, University of Iowa Carver College of Medicine, Iowa City, IA	139
805	T-5	ETCTN 10388: a Phase 1 Trial of Triapine and Lutetium 177 Dotatate in Well-differentiated Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors	Aman Chauhan, University of Kentucky, Lexington, KY	196
806	T-6	ETCTN 10450: a Phase 1 Trial of Peposertib and Lutetium Lu 177 Dotatate in Well-differentiated Somatostatin Receptor-	Aman Chauhan, University of Kentucky, Lexington, KY	199